Surgical treatment for pancreatic cancer with liver metastasis:exploration and innovation

VernacularTitle:胰腺癌肝转移的外科治疗：实践中探索探索中前行
Author: Si SHI ¹ ; Xianjun YU
Author Information

1. 复旦大学附属肿瘤医院胰腺外科　复旦大学上海医学院肿瘤学系　200032
Keywords: Pancreatic cancer; Surgical procedures, operative; Liver metastasis; Survival benefit
From: Chinese Journal of Surgery 2021;59(7):593-596
CountryChina
Language:Chinese
Abstract: The prognosis of pancreatic cancer patients with liver metastasis (PCLM) is very poor and the median overall survival(OS) is less than 6 months.The current standard treatment for PCLM is systematic chemotherapy.Though the chemotherapeutic regimens are better than gemcitabine only,the OS remains dissatisfied.A lot of retrospective studies identified that surgical treatment can only offer survival benefits for highly selected rather than entire PCLM patients.The Chinese Study Group for Pancreatic Cancer (CSPAC) has initiated a multiple-center,prospective,randomized comparison clinical trial,named CSPAC-1 to identify the standard and value of surgical treatment of PCLM patients.This manuscript reviewed the current progress of surgical treatment for pancreatic cancer with liver metastasis and looked forward to opportunities and challenges in the future.